Loading...
NPI 1770210700 · Brandon, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Silverstardx LLC is a clinical medical laboratory provider located in Brandon, Florida. This profile covers 77 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Silverstardx LLC |
| Address | 1070 E Brandon Blvd |
| City | Brandon |
| State | FL |
| ZIP | 33511 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 1, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $870.4K |
| Medicaid | $610 |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
77 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,780 | $30 | $94.4K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 100 | $590 | $59.4K |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 70 | $660 | $48.4K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 80 | $590 | $44.1K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 180 | $240 | $43.6K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 70 | $590 | $40.6K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 70 | $490 | $33.7K |
| 81185 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the calcium voltage–gated channel subunit alpha1 A gene, also called CACNA1A. | 40 | $820 | $31.9K |
| 81311 | The lab analyst performs the technical lab test to analyze variants in exon 2, such as codons 12 and 13, and exon 3, such as codon 61, for the neuroblastoma RAS viral, v–ras, oncogene homolog, also… | 90 | $290 | $27.3K |
| 81325 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the peripheral myelin protein 22, or PMP22, gene. | 30 | $750 | $25.6K |
Showing 1–10 of 77
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 77 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
77 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81307 | 19 | 30 | 320 | $660 | $508.3K |
| 81321 | 20 | 30 | 430 | $580 | $467.7K |
| 81238 | 15 | 20 | 330 | $590 | $440.3K |
| 81249 | 16 | 20 | 290 | $590 | $383.1K |
| 81223 | 17 | 20 | 340 | $490 | $329.3K |
| 81334 | 14 | 20 | 390 | $320 | $295.7K |
| 87798 | 29 | 110 | 590 | $30 | $218.6K |
| 81311 | 14 | 20 | 270 | $290 | $213K |
| 81320 | 16 | 20 | 210 | $290 | $210.6K |
| 81345 | 14 | 20 | 520 | $180 | $175.9K |
Showing 1–10 of 77
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 140 | $1 | $580 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 80 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 31 | 40 | 320 | $100 | $620K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 367 | 450 | 1,380 | $20 | $75.1K |
Other providers in the same ZIP code as Silverstardx LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.